Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Pseudomonas mendocina Biotin synthase (bioB) CSB-YP396544PZM
CSB-EP396544PZM
CSB-BP396544PZM
CSB-MP396544PZM
CSB-EP396544PZM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pseudomonas mendocina Thiazole synthase (thiG) CSB-YP396545PZM
CSB-EP396545PZM
CSB-BP396545PZM
CSB-MP396545PZM
CSB-EP396545PZM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pseudomonas mendocina Prolipoprotein diacylglyceryl transferase (lgt), partial CSB-YP396546PZM1
CSB-EP396546PZM1
CSB-BP396546PZM1
CSB-MP396546PZM1
CSB-EP396546PZM1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pseudomonas mendocina 4-hydroxybenzoate octaprenyltransferase (ubiA), partial CSB-YP396547PZM
CSB-EP396547PZM
CSB-BP396547PZM
CSB-MP396547PZM
CSB-EP396547PZM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Pseudomonas mendocina tRNA modification GTPase MnmE (mnmE) CSB-YP396548PZM
CSB-EP396548PZM
CSB-BP396548PZM
CSB-MP396548PZM
CSB-EP396548PZM-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens Fatty acid oxidation complex subunit alpha (fadB), partial CSB-YP396549STQ
CSB-EP396549STQ
CSB-BP396549STQ
CSB-MP396549STQ
CSB-EP396549STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens 2,3-bisphosphoglycerate-independent phosphoglycerate mutase (gpmI), partial CSB-YP396550STQ
CSB-EP396550STQ
CSB-BP396550STQ
CSB-MP396550STQ
CSB-EP396550STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens Glycerol kinase (glpK) CSB-YP396551STQ
CSB-EP396551STQ
CSB-BP396551STQ
CSB-MP396551STQ
CSB-EP396551STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens UDP-N-acetylmuramate--L-alanine ligase (murC) CSB-YP396552STQ
CSB-EP396552STQ
CSB-BP396552STQ
CSB-MP396552STQ
CSB-EP396552STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens Arginine--tRNA ligase (argS), partial CSB-YP396553STQ
CSB-EP396553STQ
CSB-BP396553STQ
CSB-MP396553STQ
CSB-EP396553STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens Cytochrome c-552 (nrfA) CSB-YP396554STQ
CSB-EP396554STQ
CSB-BP396554STQ
CSB-MP396554STQ
CSB-EP396554STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens 50S ribosomal protein L13 (rplM) CSB-YP396555STQ
CSB-EP396555STQ
CSB-BP396555STQ
CSB-MP396555STQ
CSB-EP396555STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens Phosphoglycerate kinase (pgk) CSB-YP396556STQ
CSB-EP396556STQ
CSB-BP396556STQ
CSB-MP396556STQ
CSB-EP396556STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens Na (+)-translocating NADH-quinone reductase subunit D, partial CSB-YP396557STQ1
CSB-EP396557STQ1
CSB-BP396557STQ1
CSB-MP396557STQ1
CSB-EP396557STQ1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens UPF0246 protein Sputcn32_1053 (Sputcn32_1053) CSB-YP396558STQ
CSB-EP396558STQ
CSB-BP396558STQ
CSB-MP396558STQ
CSB-EP396558STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens tRNA (guanine-N (1)-)-methyltransferase CSB-YP396559STQ
CSB-EP396559STQ
CSB-BP396559STQ
CSB-MP396559STQ
CSB-EP396559STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens 1,4-alpha-glucan branching enzyme GlgB (glgB), partial CSB-YP396560STQ
CSB-EP396560STQ
CSB-BP396560STQ
CSB-MP396560STQ
CSB-EP396560STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens Ribosomal RNA large subunit methyltransferase M (rlmM) CSB-YP396561STQ
CSB-EP396561STQ
CSB-BP396561STQ
CSB-MP396561STQ
CSB-EP396561STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens 2,3,4,5-tetrahydropyridine-2,6-dicarboxylate N-succinyltransferase (dapD) CSB-YP396562STQ
CSB-EP396562STQ
CSB-BP396562STQ
CSB-MP396562STQ
CSB-EP396562STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Shewanella putrefaciens (3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase CSB-YP396563STQ
CSB-EP396563STQ
CSB-BP396563STQ
CSB-MP396563STQ
CSB-EP396563STQ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>